Key Resources (listed chronologically, beginning with the most recent)
“How Will the Medicare Part D Benefit Change Under Current Law and Leading Proposals.” Cubanski, J. and Neuman, T. Kaiser Family Foundation. October 11, 2019. Available at http://allh.us/9Xqh.
“Trends in Retail Prices of Prescription Drugs Widely Used by Older Americans: 2019 Year-End Update.” Schondelmeyer, S. and Purvis, L. AARP Public Policy Institute. September 2019. Available at http://allh.us/qpDC.
“Competing Proposals to Reform Medicare Part D.” Hayes, T. American Action Forum. September 23, 2019. Available at http://allh.us/xmf3.
“What’s the Latest on Medicare Drug Price Negotiations?” Cubanski, J., Neuman, T., True, S., et al. Kaiser Family Foundation. July 23, 2019. Available at http://allh.us/C9rX.
“10 Things to Know About Medicare Part D Coverage and Costs in 2019.” Cubanski, J., Damico, A., Neuman, T. Kaiser Family Foundation. June 4. 2019. Available http://allh.us/tj6X.
“Effect of Potential Policy Change to Part D Generic Tiering on Patient Cost Sharing and Part D Plan Costs.” Sloan, C. McDonald, R., Young, J., et al. Avalere. February 28, 2019. Available at http://allh.us/gnCD.
“Redesigning Medicare Part D to Realign Incentives.” Hayes, T. American Action Forum. August 14, 2018. Available at http://allh.us/XbpG.
“Medicare Part D Improvements Help Beneficiaries and Taxpayers.” Purvis, L. AARP Public Policy Institute. July 9, 2018. Available at http://allh.us/bhcj.
Additional Resources (listed chronologically, beginning with the most recent)
“The Drug Pricing Clinic.” Holt, C., Hayes, T., Couture, B., et. al. American Action Forum. September 26, 2019. Available at http://allh.us/k7VE.
“Medicare Price Negotiation—Why Now…and How.” Frank, R. and Nichols, L. The New England Journal of Medicine. September 4, 2019. Available at http://allh.us/gy8Q.
“37.4M Part D Beneficiaries are Projected to Reach the Catastrophic Phase in 2020.” Avalere. August 28, 2019. Available at http://allh.us/rRx7.
“The Economics of Biologic Drugs.” Brill, A. and Ippolito, B. Health Affairs Blog. August 8, 2019. Available at http://allh.us/tcWY.
“Senate Finance Committee Proposes Reforms to Medicare and Medicaid Drug Policy.” Hayes, T. American Action Forum. August 6, 2019. Available at http://allh.us/4BY8.
“Evaluating the Senate Finance Committee Proposal to Restructure Medicare Part D.” Gottlieb, S. AEIdeas. July 24, 2019. Available at http://allh.us/eAcM.
“With Rebates off the Table, What’s Next for Drug Pricing and Regulation?” Thomas, S. Deloitte. July 23, 2019. Available at http://allh.us/bG9p.
“Setting the Record Straight on International Reference Pricing.” Haninger, K. The Catalyst (blog). Pharmaceutical Research and Manufacturers of America. July 16, 2019. Available at http://allh.us/x7VG.
“Sending the Wrong Price Signal: Why Do Some Brand-Name Drugs Cost Medicare Beneficiaries Less than Generics?” Dusetzina, S., Jazowski, S., Cole, A., et al. Health Affairs. July 2, 2019. Available at http://allh.us/TuVc.
“Reconciling the Seemingly Irreconcilable: How Much are We Spending on Drugs?” Kleinrock, M., Westrich, K., Buelt, L., et al. IQVIA Institute for Human Data Science and The National Pharmaceutical Council. July 2019. Available at http://allh.us/tA6w.
“Medicare Part D: Use of Pharmacy Benefit Managers and Efforts to Manage Drug Expenditures and Utilization.” GAO Highlights. July 2019. Available at http://allh.us/YTdC.
“How Drug Prices are Negotiated in Germany.” Robinson, J., Ex, P., and Panteli, D. To the Point (blog). The Commonwealth Fund. June 13, 2019. Available at http://allh.us/mYV8.
“Capping Seniors’ Out-of-Pocket Prescription Drug Costs Could Increase Medicare Prices– and Premiums.” Forbes. June 11, 2019. Available at http://allh.us/XyPt.
“Six Drug Pricing Models Have Emerged to Improve Product Access and Affordability.” Comer, B. PwC. May 29, 2019. Available at http://allh.us/cqpm.
“Is Arbitration an Answer for High Drug Prices?” Rother J. To the Point (blog). The Commonwealth Fund. May 3, 2019. Available at http://allh.us/KvR8.
“A Closer Look at International Reference Pricing for Prescription Drugs.” Capretta, J. RealClearPolicy. March 29, 2019. Available at http://allh.us/p4fB.
“Prices for and Spending on Specialty Drugs in Medicare Part D and Medicaid.” Congressional Budget Office. March 2019. Available at http://allh.us/UK3V.
“What Medicare Can Learn from Other Countries on Drug Pricing” Roy, A. The Foundation for Research on Equal Opportunity. January 11, 2019. Available at http://allh.us/hAC3.
“Proposed Changes to Medicare D Would Benefit Drug Manufacturers More than Beneficiaries.” Bishop, S. January 2, 2019. Available at http://allh.us/69FJ.
“Balancing Innovation and Competition in the Biologics Marketplace.” Korn, D. The Catalyst (blog). Pharmaceutical Research and Manufacturers of America. October 11, 2018. Available at http://allh.us/HCrk.
“Rising Costs for Patented Drugs Drive Growth of Pharmaceutical Spending in the U.S.” Blue Cross Blue Shield. The Health of America Report. May 3, 2017. Available at http://allh.us/gCTk.
“Fact Sheet: How Much Money Could Medicare Save By Negotiating Prescription Drug Prices?” Committee for a Responsible Federal Budget. April 11, 2016. Available at http://allh.us/4Kqx.
“Point of Sale Rebate Analysis in the Commercial Market: Sharing Rebates May Lower Patient Costs and Likely has Minimal Impact on Premiums.” Bunger, A., Gomberg, J., Hunter, M., et. al. Milliman and PhRMA. October 2017. Available at http://allh.us/6vKc.